Lv4
573 积分 2024-09-01 加入
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
15天前
已完结
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study
18天前
已完结
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
18天前
已完结
Eighty-nine Cases of Primary Prostatic Signet Ring Cell Carcinoma – Systematic Review
18天前
已完结
Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate?
18天前
已完结
Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
18天前
已完结
Time to Refine Prostate Cancer Epidemiology: Defining New Endpoints for Effective Screening and Causal Epidemiological Studies
18天前
已完结
Real-world clinical outcomes and prognostic factors in neuroendocrine prostate cancer
18天前
已完结
Development and validation of prognostic model for metastatic castration-resistant prostate cancer patients treated with first-line abiraterone or enzalutamide
18天前
已完结
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison
18天前
已完结
皖公网安备34019202002308
